ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 63 filers reported holding ADC THERAPEUTICS SA in Q4 2022. The put-call ratio across all filers is 1.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $595,632 | -57.6% | 664,027 | +1.7% | 0.00% | – |
| Q2 2023 | $1,403,473 | +64.3% | 652,778 | +49.1% | 0.00% | – |
| Q1 2023 | $854,001 | -36.6% | 437,949 | +24.9% | 0.00% | – |
| Q4 2022 | $1,346,968 | -1.3% | 350,773 | +23.9% | 0.00% | – |
| Q3 2022 | $1,365,000 | -16.5% | 283,012 | +37.7% | 0.00% | – |
| Q2 2022 | $1,634,000 | +29.6% | 205,568 | +139.4% | 0.00% | – |
| Q1 2022 | $1,261,000 | -11.9% | 85,865 | +21.2% | 0.00% | – |
| Q4 2021 | $1,431,000 | -37.9% | 70,843 | -16.5% | 0.00% | – |
| Q3 2021 | $2,304,000 | -62.1% | 84,857 | -66.0% | 0.00% | -100.0% |
| Q2 2021 | $6,075,000 | +21.9% | 249,527 | +22.2% | 0.00% | 0.0% |
| Q1 2021 | $4,985,000 | +41.8% | 204,227 | +86.0% | 0.00% | 0.0% |
| Q4 2020 | $3,515,000 | +915.9% | 109,811 | +946.7% | 0.00% | – |
| Q3 2020 | $346,000 | -41.3% | 10,491 | -16.6% | 0.00% | – |
| Q2 2020 | $589,000 | – | 12,585 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |